SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

٦

١ſ

Washington, D.C. 20549

				1	Vashi	ngton, D.C.	2054	.9				(OMB	APPRO\	/AL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										Estim	OMB Number: 3235 Estimated average burden hours per response:				
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
1. Name and Address of Reporting Person [*] Lewis William						ker or Tradii Pharma			NAMS	(Ch	elationship o eck all applic	able)	g Perso	on(s) to Issu 10% Ow	
(Last) (First) (Middle C/O NEWAMSTERDAM PHARMA CO N.V.	,		Date o ./06/2		Trans	saction (Mor	nth/Da	ay/Year)			Officer below)	(give title		Other (s below)	pecify
GOOIMEER 2-35		4.1	lf Ame	endment, l	Date	of Original F	iled (I	Month/Da	y/Year)	Line	<u> </u>			(Check App	
(Street) NAARDEN P7 1411	DC	_										led by Mor		One Report	
(City) (State) (Zip)															
Table I -	Non-Deri	vativ	e Se	curities	s Ac	quired, [Disp	osed o	f, or Bei	neficial	ly Owned				
1. Title of Security (Instr. 3) Date (Month/I			'ear)	Execution Date,		Code (Ir			ties Acquire I Of (D) (Ins		Beneficia Owned F	es ally following	Form:	Direct C Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				,insu: 4)
Ordinary Shares	01/0	/07/2025		2025		Α		6,960	¹⁾ A	(2)	6,960		0 D		
Table	II - Deriva (e.g.,					uired, Di , options					Owned				
Derivative Conversion Date Execu Security or Exercise (Month/Day/Year) if any			action (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	e S Ily J	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
						Date		opiration		Amount or Number of					
		Code	v	(A)	(D)	Exercisable	e Da	ate	Title	Shares					
Option (right to buy) \$25.85 01/06/2025		Code	v	(A) 32,500	(D)	(3)		ate	Ordinary Shares	32,500	\$0	32,50	0	D	

date, subject to the Reporting Person's continued service through each such date.

2. Each RSU was granted on January 7, 2025 for no consideration

3. 1/3 of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date.

/s/ William Lewis

** Signature of Reporting Person Date

01/08/2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.